Steven Prestrelski - Feb 22, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Scientific Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Feb 22, 2022
Transactions value $
-$19,411
Form type
4
Date filed
2/24/2022, 03:28 PM
Previous filing
Jan 5, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $7.75K +11.2K +1.97% $0.69 581K Feb 22, 2022 Direct
transaction XERS Common Stock Sale -$27.2K -11.2K -1.93% $2.42 570K Feb 22, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -11.2K -100% $0.00* 0 Feb 22, 2022 Common Stock 11.2K $0.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 $2.4188 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 These options are fully vested as of the date hereof.